摘要
目的:观察周剂量多西紫杉醇联合草酸铂方案治疗老年非小细胞肺癌(NSCLC)的疗效及毒副反应。方法:56例65～80岁晚期NSCLC患者,多西紫杉醇25mg/m2静脉滴注d1、d8、d15,草酸铂100mg/m2静脉滴注d1。4周为1周期,中位治疗周期数5个。结果:56例患者总有效率为39.3%(22/56),中位肿瘤进展时间(TTP)为7.3个月,中位生存期(OS)9.6个月(95%CI:8.1～12.6个月),1年生存率51.8%。最多见的3级及以上毒副反应为白细胞减少15%,神经毒性10%,无1例治疗相关性死亡。结论:多西紫杉醇联合草酸铂治疗老年晚期NSCLC疗效较好,安全性高,值得临床应用和推广。
Objective ： To observe the therapeutic effect and side effects of three-weekly docetaxel associated with oxaliplatin in aged patients with advanced non-small cell lung cancer（NSCLC）. Methods：Fifty-six elderly eligible patients between 65 and 80 years old with advanced NSCLC were treated with docetaxel 25mg/m^2 given on d1 ,d8 and d15 and oxaliplatin 100mg/m^2 given on dl through intravenous drip every 4 weeks,the patients received a median number of five cycles（range2-6）. Results：The total effective rate was 39. 3% （22/56）, and median survival time was 9. 6 months（95% CI,8.1-12. 6 months）. The 1-year survival rate was 51.8%. The most common grade 3 or higher toxicities were leucopenia（ 15% ） and neurotoxicity（ 10% ）. There were no treatment-related death. Conclusion ：There is a better therapeutic effect with slight and endurable side effects of docetaxel associated with oxaliplatin in elderly patients with advanced NSCLC, which is worth applying and advertising for the clinic use.
出处
《临床肿瘤学杂志》
CAS
2009年第12期1128-1130,共3页
Chinese Clinical Oncology
关键词
多西紫杉醇
草酸铂
老年
非小细胞肺癌
Docetaxel
Oxaliplatin
elderly
Non-small cell lung cancer
